EX-99.1

2 exhibit991-fy27q1earningsr.htm

EX-99.1 Q1 2027 EARNINGS RELEASE

Document

Exhibit 99.1

NEWS RELEASE

FOR IMMEDIATE RELEASE

MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration

•Strong start to fiscal year with net sales of $843 million growing 17% as reported and 16% organic

•U.S. net sales growth accelerated to 13%; continued robust international net sales growth of 18% as reported, 17% organic

•Advanced global pipeline ahead of schedule with FDA submission for MiniMed Fit™, CE Mark for MiniMed Flex™, Vivera™ FCL U.S. pivotal trial enrollment completion, and IDE approval for next-gen extended wear MiniMed sensor

•Raises fiscal year 2027 organic revenue growth guidance

NORTHRIDGE, Calif., September 1, 2026 – MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today reported financial results for its first quarter (Q1) of fiscal year 2027 (FY27), ended July 31, 2026.

“MiniMed delivered an excellent start to our fiscal year, with accelerating U.S. growth, continued double-digit international growth, and strong execution across our innovation pipeline,” said MiniMed Chief Executive Officer Que Dallara. “The U.S. launch of MiniMed Flex™ is doing exactly what we designed it to do: bringing new patients into the MiniMed ecosystem, driving competitive conversions, and generating significant new account growth. As our ecosystem continues to come together, we are well positioned to accelerate growth, strengthen our leadership in automated insulin delivery, and create long-term shareholder value.”

Q1 Results

•Strong double-digit net sales growth, ahead of expectations, on U.S. net sales growth acceleration and continued robust international net sales growth, even when excluding extra week benefit

•Worldwide net sales of $843 million grew 16.6% as reported and 15.8% organic; included an approximate 4-6% benefit from extra week as a result of 52-53 week fiscal calendar, consistent with prior estimate; excluding extra week benefit, the Company generated low-double digit organic growth

◦International net sales of $603 million grew 18.1% as reported and 16.9% organic, driven by Simplera™ capacity expansion and the launch of the Instinct sensor, made by Abbott

◦U.S. net sales of $240 million grew 13.1% as reported and organic. U.S. New Pumps Sold (NPS) grew over 20% year over year, driven by MiniMed Flex™ and new sensor launches

•Worldwide NPS of ~34,000, an increase of 7.7% year over year

•Worldwide CGM Attachment Rate of 69%, an increase of ~100 bps quarter over quarter

1

Q1 Highlights

•MiniMed Flex™ with Simplera™ launched in the U.S.

•MiniMed Flex™ U.S. coverage expanded to Medicare and Medicare Advantage beneficiaries

•MiniMed™ 780G system with Instinct and MiniMed Go™ with Instinct Go launched in Europe

New Announcements

•Announced August 17: MiniMed Flex™ with Instinct U.S. launch started

•Announced today:

◦MiniMed Fit™ patch pump submitted to U.S. FDA, ahead of Fall target; full U.S. launch expected Summer 2027

◦MiniMed Flex™ received CE Mark, well ahead of calendar 2026 year end target; commercial launch expected in November

◦Vivera™ fully-closed loop algorithm U.S. pivotal trial for T1 and T2 enrollment complete; on track for second half calendar 2027 U.S. launch

◦Next-gen MiniMed extended wear sensor U.S. IDE approved; expect first enrollment in pivotal trial this Fall

FY27 Outlook

For the fiscal year 2027 ending April 30, 2027, MiniMed expects:

•Organic revenue growth of approximately 10.5%, which includes the approximate 1.0 to 1.5% benefit from the extra week in Q1 FY27, a raise from the prior guidance of approximately 10%; and

•Adjusted EBITDA margin of approximately 16%, reaffirming prior guidance.

Conference Call Details

MiniMed will host a conference call at 5:45 a.m. Pacific Daylight Time (PDT) today, Tuesday, September 1, 2026, to discuss its first quarter financial results. The live audio webcast will be available on the Investor Relations section of MiniMed's website at investors.minimed.com. Within 24 hours of the webcast, an archived replay will be available for a minimum of 12 months following the call.

Investor First Quarter Earnings Presentation

An investor presentation providing additional information and analysis on fiscal first quarter results and guidance can be found on the Investor Relations section of MiniMed’s website at investors.minimed.com.

Non-GAAP Financial Measures

In addition to our financial results determined in accordance with U.S. GAAP, we present in this earnings press release certain financial measures that facilitate management’s review of the operational performance of MiniMed and serve as a basis for strategic planning; however, such financial measures are not presented in our financial statements prepared in accordance with U.S. GAAP. These financial measures are considered “non-GAAP financial measures” and are intended to supplement, and should not be considered as superior to, financ

EX-99.1

2 exhibit991-fy26q4earningsr.htm

EX-99.1 Q4 2026 EARNINGS RELEASE

Document

Exhibit 99.1

NEWS RELEASE

FOR IMMEDIATE RELEASE

MiniMed Delivers Strong Fourth Quarter and Full Fiscal Year 2026 Financial Results; Provides Fiscal Year 2027 Outlook

•Continued momentum in Q4, with net sales of $837 million growing 16% as reported and 9% organic year-over-year

•Record annual net sales performance surpasses $3B for first time, growing 14% as reported and 8% organic

•Advanced global pipeline ahead of schedule with FDA clearance for MiniMed FlexTM, CE Mark for Instinct, and global launch of MiniMed GoTM Smart MDI

NORTHRIDGE, Calif., June 3, 2026 – MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today reported financial results for its fourth quarter and full fiscal year ended April 24, 2026.

“MiniMed delivered a strong finish to our fiscal year, driven by strength in international markets and continued global adoption of the MiniMedTM 780G system,” said MiniMed Chief Executive Officer Que Dallara. “Looking ahead, we’re confident that our launches of MiniMed FlexTM and MiniMed GoTM will support long-term growth acceleration and value creation.”

Fiscal Fourth Quarter Results

•Continued momentum through the second half of the fiscal year 2026, driven by SimpleraTM and Instinct sensor, made by Abbott, CGM launches

•Worldwide net sales of $837 million grew 15.6% as reported and 8.7% organic

◦International net sales of $599 million grew 22.4% as reported and 12.2% organic, driven by Simplera capacity expansion; International New Pumps Sold (NPS) increased high-single digits sequentially

◦U.S. net sales of $238 million grew 1.5% as reported and organic, as early FDA clearance of MiniMedTM Flex shifted demand of customers who preferred to wait for the new system. Flex is on track to launch this month. U.S. momentum continued with NPS increasing mid-single digits sequentially driven by new sensor launches

•Worldwide NPS of ~42,000, an increase of 7.4% quarter-over-quarter

•Worldwide CGM Attachment Rate of 68%, an increase of 100 bps quarter-over-quarter

Fiscal Year 2026 Results

•Worldwide net sales of $3.102 billion grew 14.2% as reported and 8.0% organic

◦International net sales of $2.185 billion grew 20.6% as reported and 11.2% organic

◦U.S. net sales of $917 million grew 1.5% as reported and organic

•Worldwide New Pumps Sold of ~145,000 were unchanged year-over-year

•Worldwide CGM Attachment Rate of 66%, an increase of 700 bps year-over-year

•Ended FY26 with worldwide pump users of ~659,000

1

Fiscal Year 2026 Highlights

•Commercial launches of MiniMedTM 780G system with Instinct sensor and Simplera SyncTM sensor in the U.S.; MiniMed GoTM Smart MDI system in EMEA

•U.S. FDA clearances of MiniMed Flex™ next-generation insulin pump and MiniMed Go™ Smart MDI system

•CE Marks received for MiniMed™ 780G system with Instinct sensor, and MiniMed™ 780G system for ages 2 and older, pregnant women, and type 2 diabetes

•U.S. pharmacy formulary access for MiniMed™ 780G system and Medicare access for MiniMed™ 780G system with Instinct sensor

•Started U.S. pivotal study for ViveraTM third generation fully closed loop algorithm for type 1 and type 2 diabetes

New Announcements Made Today

•U.S. MiniMed Go™ was launched last week

•MiniMed™ 780G with Instinct will launch in Europe later this month

•MiniMed Flex™ pre-orders in the U.S. started this week and expect to begin shipping later this month

•Extension today to Abbott partnership to commercialize dual glucose-ketone sensors designed to integrate exclusively with our MiniMed smart dosing systems

Fiscal Year 2027 Outlook

For the fiscal year 2027 ending April 30, 2027, MiniMed expects:

•Organic revenue growth of approximately 10%, which includes a 1.0 to 1.5% expected benefit from the extra week in FY27

•Adjusted EBITDA margin of approximately 16%

Conference Call Details

MiniMed will host a conference call at 5:45 a.m. Pacific Daylight Time (PDT) today, Wednesday, June 3, 2026, to discuss its fourth quarter and full fiscal 2026 financial results. The live audio webcast will be available on the Investor Relations section of MiniMed's website at investors.minimed.com. Within 24 hours of the webcast, an archived replay will be available for a minimum of 12 months following the call.

Investor Presentation

An investor presentation providing additional information and analysis can be found on the Investor Relations section of MiniMed’s website at investors.minimed.com.

Non-GAAP Financial Measures

In addition to our financial results determined in accordance with U.S. GAAP, we present in this earnings press release certain financial measures that facilitate management’s review of the operational performance of MiniMed and serve as a basis for strategic planning; however, such financial measures are not presented in our financial statements prepared in accordance with U.S. GAAP. These financial measures are considered “non-GAAP f